Off-Label Use Of Malaria Drug Drives FDA To Impose REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Quinine, an old-line malaria drug, has been used off-label for night-time leg cramps, sometimes leading to serious side effects, FDA says.
You may also be interested in...
Cholesterol Endpoints Draw Scrutiny At HoFH Panels
The Metabolic and Endocrinologic Advisory Committee accepts LDL lowering as endpoint for homozygous hypercholesterolemia drugs, backing approval of Aegerion’s lomitapide by 13-2 and Genzyme’s mipomersen by 9-6, but hones in on the need for better surrogates for cardiovascular morbidity and mortality.
"Bad CME" Program May Be Developed By FDA
Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.